+91-8668442535

Impetigo Treatment Market By Drug Class (Cephalosporins, Fusidane, Lincosamide, Penicillin, Penicillin-Like Antibiotics, Pleuromutilin, Pseudomonic Acid A, Quinolone, Sulfonamides And Folic Acid Inhibitors, Tetracyclines) - Growth, Future Prospects & Competitive Analysis, 2018-2026

The global impetigo treatment market is expected to reach US$ 856.2 million by 2026, up from US$ 448.6 million in 2017, expanding at a 7.3% CAGR between 2018 and 2026. Impetigo is a bacterial skin infection caused primarily by Staphylococcus aureus or Streptococcus pyogenes. These gram-positive bacteria infect the epidermal skin layer and cause a highly contagious impetigo infection. The children are soft targets for such pathogens and infections, given their huge prevalence in areas with hot and humid climates. Depending on the causative agents, impetigo is classified as non-bullous or bullous impetigo. Non-bullous impetigo is prevalent in 70% of impetigo cases and accounts for around 10% of all-cutaneous problems in pediatric clinics. It is primarily caused by Staphylococcus aureus, Streptococcus pyogenes, or a combination of both, as opposed to the bullous form caused exclusively by S. aureus. Impetigo treatment primarily consists of infected wound care and the administration of topical or oral antibiotics.

The global impetigo treatment market is segmented on the drug class for treatment into cephalosporins, fusidane, lincosamide, penicillin, penicillin-like antibiotics, pleuromutilin, pseudomonic acid A, quinolones, sulfonamides, folic acid inhibitors, and tetracyclines. The drug classes are available in topical agent or oral form, with topical being predominantly prescribed due to effective results. The impetigo treatment market is expected to surge during the forecast period owing to the growing incidence of infection and the development of novel therapeutics. However, the evolution of methicillin-resistant S. aureus (MRSA) and macrolide-resistant Streptococcus is a major challenge to the treatment and forces manufacturers to develop more efficient antibiotics, thereby contributing to the growth of the market. As impetigo incidence rises and healthcare infrastructure expands in developing countries, the impetigo treatment market presents enormous opportunities for manufacturers.

Market Synopsis

Table: Global Impetigo Treatment Market Portraiture

During the forecast period, penicillin and penicillin-like antibiotics are expected to drive the market.

In 2017, penicillin and penicillin-like antibiotics together accounted for over 34% of the global impetigo treatment market. The two segments are collectively expected to drive the global market. Antibiotic treatment is preferred to reduce the healing duration, as most impetigo infections resolve naturally. According to the Infectious Diseases Society of America, impetigo should be treated with topical antibiotics for 5 to 7 days, such as pseudomononic acid A. Fusidic acid, another topical agent, is not available in the United States; however, physicians in Europe recommend fusidic acid, or pseudomonic acid A, as the first line of topical antibiotics. The market will surge during the forecast period owing to the development of novel drugs.

North America will continue to retain its dominance during the forecast period.

In 2017, North America led the global impetigo treatment market with around 34% of the market share in terms of value. Because of the presence of healthcare infrastructure and widespread awareness of impetigo, the United States dominated the North American market. The regional market will proliferate due to early drug approval in the United States, which aids in early market capture compared to the rest of the world's major economic regions. Europe follows North America in terms of market value due to the high awareness of impetigo. Asia Pacific is the most lucrative market for impetigo due to the growing healthcare infrastructure and rising awareness of skin infections. Furthermore, the prime incidence of impetigo infections in hot and humid areas accounts for more infections in the Asia Pacific, thereby accounting for the growth of the market.

Focus on the research and development of novel drug molecules expected to fuel the market

With the growing usage of antibiotics, the microorganisms are adapting to current antibiotics through genome modifications, which hinders the treatment pattern. Many studies have reported methicillin-resistant S. aureus (MRSA) and macrolide-resistant Streptococcus earlier, and current studies have reported fusidic acid-resistant bacteria. The evolution of these microbes burdens manufacturers with developing effective treatment options, which are expected to fuel market growth. For instance, NovaBay Pharmaceuticals, Inc. is developing NVC-422 (a topical agent) that is currently in phases II and III for impetigo treatment. The same molecule is in phase II for catheter infections. The product has performed well in the early phases and is expected to launch during the forecast period. Thus, the focus of manufacturers is on the research and development of novel drug molecules, which are expected to fuel the market. Key players in the impetigo treatment market include GlaxoSmithKline plc, Karalex Pharma, LLC, Leo Pharma A/S, Lupin Limited, NovaBay Pharmaceuticals, Inc., Pfizer, Inc., Ranbaxy Laboratories Limited, Roche Holding AG, SANDOZ GmbH, Taro Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.

Periods of History and Forecast

The research is performed by considering 2017 as the base for the study and 2018 to 2026 as the forecast period.

Report Scope by Segments

For your better understanding, the market is segmented based on the drug class and geography. The purpose of publishing this report is to aid market investors in making decisions and taking strategic initiatives.

Along with the market quantification, the key qualitative market factors such as drivers, restraints, and opportunities are also included in the report. Furthermore, the players are mapped based on their business strengths and product offerings. Key players profiled in the report include GlaxoSmithKline plc, Karalex Pharma, LLC, Leo Pharma A/S, Lupin Limited, NovaBay Pharmaceuticals, Inc., Pfizer, Inc., Ranbaxy Laboratories Limited, Roche Holding AG, SANDOZ GmbH, Taro Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.

Frequently Asked Question:

The market for Impetigo Treatment Market is expected to reach USD$ 856.2 Mn in 2026.

The Impetigo Treatment Market is expected to see significant CAGR growth over the coming years, at 7.3%.

The report is forecasted from 2018 -2026.

The base year of this report is 2017.

Karalex Pharma, LLC, Leo Pharma A/S, Lupin Limited, NovaBay Pharmaceuticals, Inc., Pfizer, Inc., Ranbaxy Laboratories Limited, Roche Holding AG, SANDOZ GmbH. are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  May 2018
Category:  Pharmaceuticals
Report ID:   59146
Report Format:   PDF
Pages:   120
Rating:    4.3 (65)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support